Michael John Mauro MD
Leader, Myeloproliferative Disorders Program; Professor, Member and Attending Physician, Memorial Sloan Kettering Cancer Center
Request Appointment
225 Summit AvenueMontvale, NJ 07645
Overview of Dr. Mauro
Dr. Michael Mauro is a hematologist in New York, NY and is affiliated with Memorial Sloan-Kettering Cancer Center. He received his medical degree from Geisel School of Medicine at Dartmouth and has been in practice 23 years. He is experienced in healthcare outcomes research, bcr-abl positive chronic myelogenous leukemia, antineoplastic agents, bcr-abl fusion proteins, and chromosome aberrations.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 1997 - 2000- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1994 - 1997
Geisel School of Medicine at DartmouthClass of 1994
Certifications & Licensure
FL State Medical License 2021 - Present
OR State Medical License 2000 - Present
NJ State Medical License 2018 - 2027
NY State Medical License 1996 - 2026
NH State Medical License 2024 - 2024
NC State Medical License 2020 - 2022
ME State Medical License 2020 - 2021
American Board of Internal Medicine Hematology- Join now to see all
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013, 2017
- CMS Meaningful Use Stage 2 Certification Sunrise Ambulatory Care, Allscripts, 2013, 2017
- CMS Meaningful Use Stage 2 Certification MyMSK, Memorial Sloan Kettering, 2013, 2017
Clinical Trials
- Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia Start of enrollment: 2008 May 01
- Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML Start of enrollment: 2008 Aug 14
- A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL Start of enrollment: 2014 Apr 24
Publications & Presentations
PubMed
- A plain language summary of how the body processes a lower-dose nilotinib tablet (Danziten™) compared to the existing capsule (Tasigna®).Michael Mauro, Jerald Radich, Dan Douer
Future Oncology. 2026-02-01 - 4 citationsExpert consensus definition of treatment intolerance in chronic myeloid leukemia in chronic phase.Ehab Atallah, Michael S Broder, Onyee Chan, Kathryn E Flynn, Jeffrey A Gilreath
Hematology. 2025-12-01 - 12 citationsApoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia.Antonino Glaviano, Ellen Weisberg, Hiu Y Lam, Donavan J J Tan, Andrew J Innes
Nature Reviews. Clinical Oncology. 2025-11-01
Abstracts/Posters
- Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid LeukemiaMichael J. Mauro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Cardiovascular (CV)-Related Hospitalizations and Associated Costs Among US Patients in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloi...Michael J. Mauro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II StudyMichael J. Mauro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- A multicenter, randomized phase III study of asciminib (ABL001) versus bosutinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously t...2019 ASCO Annual Meeting - 6/1/2019
- Dosing Patterns of Dasatinib Use in Simplicity, an Observational Study in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients (pts) in Routine Clinical Practice2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Cardiovascular Mortality Among CML Patients in the Pre-TKI and TKI Eras: A SEER Analysis 1992-20042018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Authored Content
- Efficacy and Safety Outcomes by Baseline Comorbidity and Age in Patients Newly Diagnosed with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Treated with Dasatinib or Imatinib in DASISIONOctober 2017
Press Mentions
Dr Ashwin Kishtagari’s Top 4 Picks from SOHO 2025October 9th, 2025- Farhad Ravandi, MD, on AML: Highlights of Ongoing ResearchSeptember 16th, 2025
- Molecular Monitoring Deficient in Older Adults with CMLMay 2nd, 2023
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Massachusetts Blue Care Elect PPO
CIGNA Open Access
CIGNA PPO
First Choice
First Health PPO
Great West PPO
Health Net Oregon PPOHumana ChoiceCare Network PPO
Lifewise Health Plan of Oregon
Multiplan PHCS PPO
Multiplan PPO
ODS Network
Pacificare HMO
PacificSource Preferred PSN
Providence Health System Preferred PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
